Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Apria $139.7 million stock offering
We advised the underwriters on the SEC-registered equity offering
Mathys sale to DJO
We are advising the Mathys family on the sale
Ayala Pharmaceuticals $20 million at-the-market offering
We advised the sales agent on the stock offering
Oak Street Health $747.2 million secondary offering
We advised the joint book-running managers on the equity offering
Esco Lifesciences $200 million Series A financing
We are advising Esco Lifesciences on its Series A financing
Fresenius Medical Care $1.5 billion notes offering
We advised the initial purchasers on the Rule 144A / Regulation S notes offering
Charles River Laboratories acquisition of Vigene Biosciences
We are advising Charles River on the acquisition
Accuray private exchange offers
We advised Accuray on its exchange of convertible senior notes
ImmunityBio $500 million at-the-market offering
We advised the sales agent in connection with the equity offering
Vaccitech $110.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing